News 04 Oct 2022 Daxor Corporation to Exhibit & Present at the Medaxiom Cardiovascular Transforum Conference Fall’22 to Advance Awareness & Further Adoption of Daxor’s Blood Volume Diagnostic (BVA-100®) admin
News 04 Oct 2022 Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting admin
News 03 Oct 2022 New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55% admin
News 03 Oct 2022 New Data Shows 85% Reduction in One-Year Mortality for Medicare Heart Failure Patients With BVA-Guided Care admin
News 03 Oct 2022 New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures admin
News 26 Sep 2022 Daxor Corporation to Exhibit at the Annual Scientific Meeting of the Heart Failure Society of America admin
News 06 Sep 2022 Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment Conference admin
News 29 Aug 2022 Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders admin
News 25 Aug 2022 Daxor Corporation Reports a 92.6 Percent Revenue Increase in Diagnostic Operating Division in Form N-CSR Filing for the Six Months Ended June 30, 2022 admin
News 24 Aug 2022 Daxor Corporation to Report First Half 2022 Financial Results on Thursday, August 25, 2022 & Provide Corporate Update admin
